Ofri Mosenzon Selected Research

Metformin (Glucophage)

4/2021	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
1/2021	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
11/2020	Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
1/2020	Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
1/2019	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.
1/2019	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ofri Mosenzon Research Topics

Disease

64	Type 2 Diabetes Mellitus (MODY) 01/2022 - 10/2013
33	Myocardial Infarction 01/2022 - 10/2013
28	Heart Failure 01/2022 - 10/2013
19	Diabetes Mellitus 11/2021 - 10/2014
15	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2016
11	Ischemic Stroke 01/2022 - 06/2015
9	Chronic Renal Insufficiency 01/2022 - 10/2014
9	Kidney Diseases (Kidney Disease) 01/2022 - 01/2018
7	Weight Loss (Weight Reduction) 01/2022 - 01/2018
7	Hypoglycemia (Reactive Hypoglycemia) 10/2021 - 08/2016
6	Obesity 01/2022 - 01/2018
6	Stroke (Strokes) 01/2022 - 10/2013
6	Body Weight (Weight, Body) 01/2022 - 11/2020
5	Albuminuria 01/2021 - 04/2015
4	Overweight 01/2022 - 01/2020
4	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021 - 01/2017
4	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2021 - 01/2019
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 11/2014
3	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2020
3	Nausea 01/2022 - 01/2018
3	Body Weight Changes 04/2021 - 01/2020
3	Atrial Fibrillation 01/2021 - 11/2019
3	Pancreatitis 11/2020 - 10/2013
3	Infections 01/2020 - 01/2019
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 01/2019
2	Glycosuria 10/2021 - 01/2018
2	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2021 - 11/2020
2	Renal Insufficiency (Renal Failure) 01/2018 - 08/2016
2	Chronic Pancreatitis 09/2014 - 10/2013
1	Constipation 01/2022
1	Vomiting 01/2022
1	Asthma (Bronchial Asthma) 11/2021
1	Insulin Resistance 10/2021
1	Coma (Comas) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Thyroid Neoplasms (Thyroid Cancer) 11/2020
1	Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis) 11/2020
1	Urologic Neoplasms (Urological Cancer) 01/2020
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Peripheral Arterial Disease 01/2020
1	Ventricular Remodeling 01/2020
1	Neoplasms (Cancer) 01/2020
1	Weight Gain 01/2020
1	Coronary Artery Disease (Coronary Atherosclerosis) 11/2019
1	Hypersensitivity (Allergy) 01/2019
1	Anaphylaxis (Anaphylactic Shock) 01/2019

Drug/Important Bio-Agent (IBA)

25	dapagliflozinIBA 01/2022 - 01/2018
21	saxagliptin FDA Link 11/2021 - 10/2013
18	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 08/2016
13	Liraglutide FDA Link 01/2022 - 01/2018
12	SodiumIBA 01/2022 - 01/2018
10	semaglutideIBA 01/2022 - 01/2018
10	Sodium-Glucose Transport ProteinsIBA 01/2021 - 01/2019
9	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2018
8	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2018
7	Insulin (Novolin)FDA Link 04/2021 - 11/2014
6	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2018
6	CreatinineIBA 01/2022 - 01/2018
6	Biomarkers (Surrogate Marker)IBA 11/2021 - 12/2016
6	Metformin (Glucophage)FDA LinkGeneric 04/2021 - 01/2019
6	Pharmaceutical PreparationsIBA 10/2020 - 08/2016
5	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 12/2018
5	AlbuminsIBA 01/2022 - 01/2018
5	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 01/2018
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 01/2020
3	pro-brain natriuretic peptide (1-76)IBA 11/2021 - 01/2018
3	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2021 - 10/2014
3	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 08/2016
2	Troponin T (Troponin T1)IBA 11/2021 - 12/2016
2	TicagrelorIBA 01/2021 - 01/2021
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 01/2021
2	DiureticsIBA 01/2020 - 11/2016
1	LDL CholesterolIBA 01/2022
1	HDL LipoproteinsIBA 01/2022
1	HDL CholesterolIBA 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022
1	PotassiumIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	ORALIT (ORS)IBA 11/2021
1	empagliflozinIBA 10/2021
1	Sitagliptin Phosphate (Januvia)FDA Link 04/2021
1	Peptides (Polypeptides)IBA 04/2021
1	darapladibIBA 01/2021
1	Thyroid HormonesIBA 01/2021
1	Factor Xa (Coagulation Factor Xa)IBA 01/2021
1	SymportersIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2020
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2020
1	lixisenatideIBA 01/2019
1	Exenatide (Byetta)FDA Link 01/2019

Therapy/Procedure

11	Therapeutics 10/2021 - 01/2003
4	Glycemic Control 11/2020 - 01/2017
3	Surgical Amputation (Amputations) 01/2022 - 01/2020
3	Secondary Prevention 01/2021 - 01/2018
1	Withholding Treatment 01/2021
1	Psychology Biofeedback (Biofeedback) 01/2021
1	Precision Medicine 12/2020
1	Contraindications 10/2020
1	Kidney Transplantation 01/2019